Continuous versus intermittent antibiotics for non‐cystic fibrosis bronchiectasis
References
Additional references
Aliberti S, Masefield S, Polverino E, De Soyza A, Loebinger MR, Menendez R, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. European Respiratory Journal 2016;48(3):632‐47. [PUBMED: 27288031]
Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309(12):1251‐9. [PUBMED: 23532241]
Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, et al. Aztreonam for inhalation solution in patients with non‐cystic fibrosis bronchiectasis (AIR‐BX1 and AIR‐BX2): two randomised double‐blind, placebo‐controlled phase 3 trials. Lancet 2014;2(9):738‐49. [PUBMED: 25154045]
Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non‐cystic fibrosis bronchiectasis: a systematic review. European Respiratory Journal 2014;44(2):382‐93. [PUBMED: 24925920]
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012;186(7):657‐65. [PUBMED: 22744718]
Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non‐cystic fibrosis bronchiectasis. Molecular Immunology 2013;55(1):27‐34. [PUBMED: 23088941]
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. American Journal of Respiratory and Critical Care Medicine 2014;189(5):576‐85. [PUBMED: 24328736]
Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. European Respiratory Journal 2015;45(5):1446‐62. [PUBMED: 25792635]
Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Bronchiectasis in indigenous children in remote Australian communities. Medical Journal of Australia 2002;177(4):200‐4. [PUBMED: 12175325]
Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Medical Journal of Australia 2010;193(6):356‐65. [PUBMED: 20854242]
Cole PJ. Inflammation: a two‐edged sword ‐ the model of bronchiectasis. European Journal of Respiratory Diseases. Supplement 1986;147:6‐15. [PUBMED: 3533593]
Cole P. The damaging role of bacteria in chronic lung infection. Journal of Antimicrobial Chemotherapy 1997;40 Suppl A:5‐10. [PUBMED: 9484867]
de la Rosa D, Martínez‐García MA, Olveira C, Girón R, Máiz L, Prados C. Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. Chronic Respiratory Disease 2016;13(4):361‐71. [PUBMED: 27072020]
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356(9237):1255‐9. [PUBMED: 11072960]
Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. European Respiratory Journal 1996;9(8):1601‐4. [PUBMED: 8866579]
Finch S, McDonnell MJ, Abo‐Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Annals of the American Thoracic Society 2015;12(11):1602‐11. [PUBMED: 26356317]
Foweraker J, Wat D. Microbiology of non‐CF bronchiectasis [Bronchiectasis]. In: Floto RA, Haworth CS editor(s). European Respiratory Society Monographs. Vol. 52, European Respiratory Society, 2011:68‐96.
Gibson GJ, Loddenkemper R, Lundback B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. European Respiratory Journal2013; Vol. 42, issue 3:559‐63. [PUBMED: 24000245]
Goeminne PC, De Soyza A. Bronchiectasis: how to be an orphan with many parents?. European Respiratory Journal2016; Vol. 47, issue 1:10‐3. [PUBMED: 26721955]
GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 30 January 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Habesoglu MA, Ugurlu AO, Eyuboglu FO. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Annals of Thoracic Medicine 2011;6(3):131‐6. [PUBMED: 21760844]
Hansen MP, Thorning S, Aronson JK, Beller EM, Glasziou PP, Hoffmann TC, et al. Adverse events in patients taking macrolide antibiotics versus placebo for any indication. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD011825]
Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. American Journal of Respiratory and Critical Care Medicine 2014;189(8):975‐82. [PUBMED: 24625200]
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hnin K, Nguyen C, Carson KV, Evans DJ, Greenstone M, Smith BJ. Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD001392.pub3]
Hui C, Lin MC, Jao MS, Liu TC, Wu RG. Previous antibiotic exposure and evolution of antibiotic resistance in mechanically ventilated patients with nosocomial infections. Journal of Critical Care 2013;28(5):728‐34. [DOI: 10.1016/j.jcrc.2013.04.008]
Joish VN, Spilsbury‐Cantalupo M, Operschall E, Luong B, Boklage S. Economic burden of non‐cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Applied Health Economics and Health Policy 2013;11(3):299‐304. [PUBMED: 23580074]
Kapur N, Masters IB, Newcombe P, Chang AB. The burden of disease in pediatric non‐cystic fibrosis bronchiectasis. Chest 2012;141(4):1018‐24. [PUBMED: 21885727]
Martínez‐García MA, Soler‐Cataluña JJ, Perpìñá‐Tordera M, Román‐Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non‐cystic fibrosis bronchiectasis. Chest 2007;132(5):1565‐72. [PUBMED: 17998359]
Miravitlles M, Monteagudo M, Rodríguez T, Barrecheguren M, Simonet P, Sáez M, et al. Prevalence of bronchiectasis in four European countries. Pneumologie2016; Vol. 70, issue 1:A57.
Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis (non‐CF) Guideline Group. British Thoracic Society Guidelines for non‐CF bronchiectasis. Thorax 2010;65(Suppl1):i1–58.
Polverino E, Cacheris W, Spencer C, Operschall E, Donnell AE. Global burden of non‐cystic fibrosis bronchiectasis: A simple epidemiological analysis. European Respiratory Journal 2014;40(Suppl 56):P3983.
Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal 2016;47(1):186‐93. [PUBMED: 26541539]
Redondo M, Keyt H, Dhar R, Chalmers JD. Global impact of bronchiectasis and cystic fibrosis. Breathe 2016;12(3):222‐35.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population‐based estimation of disease prevalence. European Respiratory Journal2015; Vol. 46, issue 6:1805‐7. [PUBMED: 26293498]
Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, Rivett DW, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Annals of the American Thoracic Society 2014;11(4):496‐503. [PUBMED: 24592925]
Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis‐associated hospitalizations in the United States, 1993‐2006. Chest 2010;138(4):944‐9. [PUBMED: 20435655]
Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309(12):1260‐7. [PUBMED: 23532242]
Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand national incidence of bronchiectasis "too high" for a developed country. Archives of Disease in Childhood 2005;90(7):737‐40. [PUBMED: 15871981]
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine 2005;12(4):205‐9.
Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. European Respiratory Journal 1997;10(8):1754‐60. [PUBMED: 9272915]
Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet 2012;380(9842):660‐7. [PUBMED: 22901887]
